Recombinant TNF alpha (Infliximab Biosimilar) anticorps

N° du produit ABIN7200661

Cet anticorps anti-TNF alpha (Infliximab Biosimilar) est un anticorps Souris Monoclonal détectant TNF alpha (Infliximab Biosimilar) dans FACS et in vivo. Adapté pour Humain.

Aperçu rapide pour Recombinant TNF alpha (Infliximab Biosimilar) anticorps (ABIN7200661)

Antigène: TNF alpha (Infliximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNF alpha (Infliximab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Clone: CA2

Détail du produit anti-TNF alpha (Infliximab Biosimilar) anticorps

Fonction: Infliximab Biosimilar, TNF alpha Monoclonal Antibody

Specificité: The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.

Attributs du produit: Recombinant Chimeric IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur TNF alpha (Infliximab Biosimilar)

Antigène: TNF alpha (Infliximab Biosimilar)

Classe de substances: Biosimilar

Sujet: Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.